ZOLMITRIPTAN TABLET

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

ZOLMITRIPTAN

Доступно од:

PRO DOC LIMITEE

АТЦ код:

N02CC03

INN (Међународно име):

ZOLMITRIPTAN

Дозирање:

2.5MG

Фармацеутски облик:

TABLET

Састав:

ZOLMITRIPTAN 2.5MG

Пут администрације:

ORAL

Јединице у пакету:

6/30

Тип рецептора:

Prescription

Терапеутска област:

SELECTIVE SEROTONIN AGONISTS

Резиме производа:

Active ingredient group (AIG) number: 0134381001; AHFS:

Статус ауторизације:

CANCELLED POST MARKET

Датум одобрења:

2021-04-07

Карактеристике производа

PRODUCT MONOGRAPH
PR
ZOLMITRIPTAN
Zolmitriptan Film-Coated Tablets, House Standard
2.5 mg
PR
ZOLMITRIPTAN ODT
Zolmitriptan Orally Dispersible Tablets, House Standard
2.5 mg
5-HT1 RECEPTOR AGONIST
MIGRAINE THERAPY
DATE OF REVISION:
MARCH 4, 2021
PRO DOC LTÉE
2925, boul. Industriel
Laval, Québec
H7L 3W9
Submission Control No.: 248801
Zolmitriptan
Zolmitriptan PM-E.pdf
Pg. 1
_ _
_ZOLMITRIPTAN and ZOLMITRIPTAN ODT Product Monograph _
_Page 2 of 41 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
...............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
5
ADVERSE REACTIONS
............................................................................................
12
DRUG INTERACTIONS
..............................................................................................
18
DOSAGE AND ADMINISTRATION
...........................................................................
20
OVERDOSAGE
............................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 22
STORAGE AND STABILITY
......................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 25
PART II: SCIENTIFIC INFORMATION
............................................................................
26
PHARMACEUTICAL
INFORMATION.......................................................................
26
CLINICAL
TRIALS........................................................................